Close Menu

NEW YORK – Roche said on Thursday that its Elecsys IL-6 test to identify severe inflammatory response in COVID-19 patients received Emergency Use Authorization from the US Food and Drug Administration. 

The test measures levels of interleukin 6, a biomarker that indicates acute inflammation, in human serum or plasma and can be used to identify COVID-19 patients at high risk of intubation with mechanical ventilation. IL-6 is released early during a severe infection, which helps physicians identify severely ill COVID-19 patients as quickly as possible, Roche said in a statement. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.